New Understanding of Skin Hardening Syndromes Found PDF Print E-mail
Thursday, 19 May 2011 09:52
New details about the underlying mechanisms of skin hardening syndromes, morphea, have been discovered by researchers from Boston University School of Medicine (BUSM). Morphea, also known as localized scleroderma, is a disorder characterized by excessive collagen deposition leading to thickening of the dermis, subcutaneous tissues, or both.

Thomas Ruenger, MD, PhD, a professor and vice-chair of dermatology at BUSM, and colleagues connected pharmacological properties of the Novartis Pharma AG drug called balicatib to the skin disorder for the first time after investigating adverse reactions suffered by patients participating in a clinical trial for the treatment of osteoporosis. The team’s findings appear online in the Journal of the American Academy of Dermatology.

Morphea is rare. The estimated incidence is approximately 25 cases per million population per year. Drug-induced morphea is even rarer as noted by Oliver Kraigher, MD and colleagues in their 2009 Archives of Dermatology article, “To our knowledge, only 10 cases of drug-associated morphea have been reported, induced by vitamin K1 (phytonadione), vitamin B12 (cyanocobalamin), penicillamine, bromocriptine, pentazocine, 5-hydroxytryptophan/carbidopa combination, and balicatib. In half of these cases, partial or complete response was achieved after the drug treatment was stopped.”

Balicatib was developed recently as an osteoporosis drug that can inhibit CathepsinK (catK), an enzyme involved with bone degradation. A phase II study of balicatib in women with postmenopausal osteoporosis showed dose-dependent reduction in levels of bone resorptive markers and an increase in bone mineral density, but a small number of patients developed morphealike skin changes.

Most of the patients in the balicatib trial who experienced the morphea skin changes did so in the neck, chest and abdomen regions.

Balicatib is lysosomotropic and can accumulate in lysosomes with a high enough concentration to cause off-target inhibition of other types of cathepsins, some of which are expressed by skin fibroblasts.

After examining the cases and relating them to recent reports of cathepsin K expression in the skin and the role of cathepsin K in degrading collagen and elastin, the investigators determined that the changes were a direct effect of the drug.

This case study proves that catK affects the skin as well as bones, and marks the first time that skin hardening can be convincingly linked to the pharmacologic properties of a drug.

"This observation emphasizes the importance of intracellular collagen degradation in the skin, a pathway so far vastly underappreciated," said Thomas Ruenger, MD, PhD, a professor and vice-chair of dermatology at BUSM. "This observation also sheds new light on our understanding of the mechanisms involved in morphea, or skin hardening. Failed collagen degradation has so far not been thought to cause morphea."

The researchers believe these findings have far-reaching implications for osteoporosis patients and those suffering from skin hardening syndromes.

Source: Bates, R. (2011), "New Understanding of Skin Hardening Syndromes Found"; source article can be viewed here.
 
More articles :

» Beware of Skin Signs of Illness and Disease

While moisturizers and make-up, facial peels and Botox can make our skin look beautiful and young, sometimes the external skin discolorations, blemishes, blotches or other unsightly marks we seek to remove are actually signs of an underlying...

» Treatment of Ulcers In Scleroderma

Digital ulcers may develop in patients. Most systemic sclerosis patients will have digital ulcers at some point. In some, ulcers are persistent. Sometimes they progress to and amputation. These Scleroderma ulcers are difficult to treat because of...

» HSCT Benefits In Early Diffuse Cutaneous Systemic Sclerosis

Initial results from an international, investigator-initiated, open label phase 3 trial, presented at EULAR 2012, indicate that haematopoietic stem cell transplantation (HSCT) results in better long-term survival than conventional treatment for...

» 7 Tips For Maintaining Healthier Skin In Scleroderma

Scleroderma is a rare, connective tissue disease in which the body’s normal tissue is replaced with thick, dense tissue, due to the overproduction of collagen. Although can affect other parts of the body including the kidneys, hearts, and...

» Long Term Methotrexate Therapy Beneficial for Juvenile Localized Scleroderma

Researchers in Italy evaluated 65 patients with Juvenile Localized (JLS; or) previously enrolled in a double blind, randomized control trial and treated for the first 3 months with oral methotrexate (MTX; 15 mg/m2 weekly) and prednisone (1 mg/kg...

» Getting to the Root of Raynaud’s

Dr. Fredrick Wigley is a professor of medicine at Johns Hopkins School of Medicine and director of the Johns Hopkins Scleroderma  Center. A rheumatologist, he has been studying Raynaud’s since 1978. The New York Times recently interviewed Dr....